Dyne Therapeutics (NASDAQ:DYN) Rating Reiterated by Chardan Capital

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a research report issued on Monday, Benzinga reports. They currently have a $31.00 target price on the stock. Chardan Capital’s price target suggests a potential upside of 20.86% from the company’s current price.

Several other research firms have also recently weighed in on DYN. Stifel Nicolaus lifted their price target on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Piper Sandler boosted their price target on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of Dyne Therapeutics in a research note on Friday, May 3rd. Oppenheimer reaffirmed an “outperform” rating and set a $47.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, March 26th. Finally, Morgan Stanley assumed coverage on Dyne Therapeutics in a research report on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 target price for the company. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.75.

Dyne Therapeutics Stock Down 2.3 %

NASDAQ:DYN opened at $25.65 on Monday. The firm has a market capitalization of $2.24 billion, a P/E ratio of -6.46 and a beta of 1.00. The company has a fifty day moving average of $26.47 and a 200 day moving average of $18.83. Dyne Therapeutics has a 52 week low of $6.40 and a 52 week high of $30.27.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, March 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.17). As a group, analysts anticipate that Dyne Therapeutics will post -3.27 EPS for the current year.

Insider Activity

In other Dyne Therapeutics news, insider Wildon Farwell sold 5,493 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $25.07, for a total transaction of $137,709.51. Following the completion of the sale, the insider now directly owns 163,503 shares in the company, valued at approximately $4,099,020.21. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, COO Susanna Gatti High sold 1,591 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $25.85, for a total transaction of $41,127.35. Following the transaction, the chief operating officer now directly owns 186,291 shares of the company’s stock, valued at $4,815,622.35. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Wildon Farwell sold 5,493 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $25.07, for a total value of $137,709.51. Following the sale, the insider now directly owns 163,503 shares in the company, valued at $4,099,020.21. The disclosure for this sale can be found here. Insiders sold 1,875,432 shares of company stock worth $44,368,530 over the last three months. 20.77% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DYN. Wetzel Investment Advisors Inc. purchased a new position in shares of Dyne Therapeutics during the first quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Dyne Therapeutics by 355.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock valued at $94,000 after buying an additional 5,541 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Dyne Therapeutics by 58.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company’s stock worth $75,000 after buying an additional 3,092 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of Dyne Therapeutics by 95.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company’s stock worth $83,000 after acquiring an additional 4,552 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of Dyne Therapeutics in the fourth quarter worth $172,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.